Corvus Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Corvus Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.28M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($62.29M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($27.03M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($41.31M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | ($43.24M) | Mar 19, 2024 |
| FY2021 | Dec 31, 2020 | $27.35M | Mar 10, 2022 |
| FY2021 | Sep 30, 2020 | ($9.80M) | Mar 10, 2022 |
| FY2021 | Jun 30, 2020 | ($10.61M) | Mar 10, 2022 |
| FY2021 | Mar 31, 2020 | ($12.94M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($11.05M) | Mar 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($42.97M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($27.55M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($23.41M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($32.57M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | ($38.63M) | Mar 19, 2024 |
| FY2021 | Dec 31, 2020 | ($43.76M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($48.85M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($49.22M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($56.52M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | ($36.98M) | Mar 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.72M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $19.39M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $16.53M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $24.47M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $29.12M | Mar 19, 2024 |
| FY2021 | Dec 31, 2020 | $31.83M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $37.98M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $38.59M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $46.31M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $29.36M | Mar 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.80M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($25.42M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($23.94M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($27.02M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | ($36.72M) | Mar 19, 2024 |
| FY2021 | Dec 31, 2020 | ($34.78M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($37.32M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($40.99M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($46.21M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | ($27.86M) | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $174.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $34.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $269.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $5.0K | Mar 19, 2024 |
| FY2021 | Dec 31, 2020 | $76.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $25.0K | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $355.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $266.0K | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $2.20M | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $1.75M | Mar 1, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.12M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $68.91M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $45.55M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $68.24M | Mar 19, 2024 |
| FY2021 | Dec 31, 2021 | $109.46M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $85.53M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $83.65M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $118.23M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $94.78M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $140.15M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.91M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $36.34M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $6.87M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $12.13M | Mar 19, 2024 |
| FY2021 | Dec 31, 2021 | $12.29M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $13.38M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $12.54M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.90M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $9.94M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $7.35M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.21M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $32.57M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $38.68M | Mar 12, 2026 |
| FY2025 | Dec 31, 2022 | $56.12M | Mar 12, 2026 |
| FY2024 | Dec 31, 2021 | $97.16M | Mar 25, 2025 |
| FY2023 | Dec 31, 2020 | $72.15M | Mar 19, 2024 |
| FY2021 | Dec 31, 2019 | $71.11M | Mar 28, 2023 |
| FY2021 | Dec 31, 2018 | $110.34M | Mar 10, 2022 |
| FY2020 | Dec 31, 2017 | $84.84M | Mar 25, 2021 |
| FY2019 | Dec 31, 2016 | $132.80M | Mar 9, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($412.29M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($397.01M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($334.72M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($307.69M) | Mar 19, 2024 |
| FY2021 | Dec 31, 2021 | ($266.38M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($223.14M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($217.15M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($170.47M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($123.53M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($67.87M) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.58M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $8.74M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $12.62M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $13.16M | Mar 19, 2024 |
| FY2021 | Dec 31, 2021 | $63.46M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $16.46M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $5.15M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $39.20M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $45.11M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $5.05M | Mar 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 25, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 10, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 10, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 10, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 10, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 10, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 25, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 10, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 10, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 10, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 10, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 10, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 74.70M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 67.90M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 49.04M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 46.55M | Mar 19, 2024 |
| FY2021 | Dec 31, 2021 | 46.55M | Mar 10, 2022 |
| FY2021 | Dec 31, 2020 | 28.37M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 27.95M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 29.32M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 21.04M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 20.92M | Mar 1, 2018 |